REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
Covid-19

Collaboration to Test New COVID-19 Drug in First Clinical Trial Worldwide

new covid-19 drug
Sheba and Merck & Co., Inc. collaborate to trial a novel coronavirus drug that prevents replication of the virus.

Sheba Medical Center is the first hospital in the world to collaborate with Merck & Co., Inc., to conduct a COVID-19 clinical trial of their drug, Molnupiravir (MK-4482). Originally designed to combat the flu, the medication is being tested as a treatment for COVID-19 patients who have symptoms and were diagnosed within the last 10 days. It is intended to be taken for five days at 12-hour intervals.

The drug works by causing mutations in the enzyme responsible for replicating the virus. By blocking replication, the disease is prevented from worsening – effectively stopping it.

Presently, Molnupiravir is in Phase II/III clinical trial to test safety and efficacy. If it is found to be safe and effective, the drug is expected to be approved at the end of the trial as a treatment for patients who are both in and out of the hospital. The COVID-19 clinical trial will continue in other international hospitals.

Thus far, Phase I results in US trials have been promising. Preclinical trials last spring also produced encouraging results, both in cells and in animals.

Related
virtual care
Nuvo Group and Sheba Develop AI-Powered Gestational Diabetes Management Platform
A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba’s Beyond Virtual Hospital, simplifying care for pregnant…
Read More
pain treatment for pancreatic cancer
Breakthrough Study: Radiation Therapy Effective for Pain Management in Cancer Patients
Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much…
Read More
arc center
News Nov 30.
Real-Time Detection of Cancerous Biomarkers With Artificial Intelligence
Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all…
Read More